RxDoctor Payments Data

Janiece Andrews, MD

Psychiatry · Camp Hill, PANPI 1477501567

Payments from drug & device makers

$16,992in general payments, 2019–2025

Across 868 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Teva Pharmaceuticals USA, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Neurocrine Biosciences, Inc.$1K
  • Johnson & Johnson$1K
  • plus $7K from 30 others

What the payments were for

  • Food & beverage$16,79299%
  • Education$1991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,992 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$30,073
Medicare patients
28
Services billed
289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate15$128,270
AbilifyAripiprazole13$11,501
Aripiprazole20$6,175
Venlafaxine Hcl ErVenlafaxine Hcl18$2,197
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine46$2,017
Bupropion XlBupropion Hcl29$1,853
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine21$1,657
Clomipramine Hcl11$1,126
Desvenlafaxine Succinate ErDesvenlafaxine Succinate18$948
Armodafinil14$714
Dextroamphetamine Sulfate13$540
Haloperidol11$540
Clonazepam49$408
Topiramate15$341
Lorazepam33$306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,229$128,27015 claims
E.r. Squibb & Sons, L.L.C.Abilify$87$11,50113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in Camp Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →